Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

FDA approval for Lucentis

July 3, 2006

NDA submission for AzaSite in bacterial conjunctivitis

July 3, 2006

Macugen studied in phase IV maintenance trial

June 29, 2006

Lumigan approved for first-line use

June 26, 2006

rEV-131 studied in new trial for inflammation following cataract surgery

June 23, 2006

ISTA licenses new investigational glaucoma products from Senju

June 22, 2006

Series A financing to fund development of Danube's oral glaucoma therapy

June 19, 2006

MabThera recommended for European approval for rheumatoid arthritis

June 7, 2006

Initial increase in vision from baseline with monthly dosing of Lucentis

June 7, 2006

New therapeutic agents for ocular disorders disclosed

June 6, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...